PMID- 23826736
OWN - NLM
STAT- MEDLINE
DCOM- 20131211
LR  - 20221207
IS  - 1365-2567 (Electronic)
IS  - 0019-2805 (Print)
IS  - 0019-2805 (Linking)
VI  - 140
IP  - 3
DP  - 2013 Nov
TI  - Roles of cathelicidin-related antimicrobial peptide in murine osteoclastogenesis.
PG  - 344-51
LID - 10.1111/imm.12146 [doi]
AB  - Cathelicidin-related antimicrobial peptide (CRAMP) not only kills bacteria but 
      also binds to lipopolysaccharide (LPS) to neutralize its activity. CRAMP is 
      highly expressed in bone marrow and its expression is reported to be up-regulated 
      by inflammatory and infectious stimuli. Here, we examined the role of CRAMP in 
      murine osteoclastogenesis. Osteoclasts were formed in co-cultures of osteoblasts 
      and bone marrow cells in response to 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2 D3 ], 
      prostaglandin E2 (PGE2 ), and Toll-like receptor (TLR) ligands such as LPS and 
      flagellin through the induction of receptor activator of nuclear factor-kappaB ligand 
      (RANKL) expression in osteoblasts. CRAMP inhibited the osteoclastogenesis in 
      co-cultures treated with LPS and flagellin, but not in those treated with 
      1alpha,25(OH)2 D3 or PGE2 . Although bone marrow macrophages (BMMs) highly expressed 
      formyl peptide receptor 2 (a receptor of CRAMP), CRAMP showed no inhibitory 
      effect on osteoclastogenesis in BMM cultures treated with RANKL. CRAMP suppressed 
      both LPS- and flagellin-induced RANKL expression in osteoblasts and tumour 
      necrosis factor-alpha (TNF-alpha) expression in BMMs, suggesting that CRAMP neutralizes 
      the actions of LPS and flagellin. LPS and flagellin enhanced the expression of 
      CRAMP mRNA in osteoblasts. Extracellularly added CRAMP suppressed LPS- and 
      flagellin-induced CRAMP expression. These results suggest that the production of 
      CRAMP promoted by LPS and flagellin is inhibited by CRAMP released by osteoblasts 
      through a feedback regulation. Even though CRAMP itself has no effect on 
      osteoclastogenesis in mice, we propose that CRAMP is an osteoblast-derived 
      protector in bacterial infection-induced osteoclastic bone resorption.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - Horibe, Kanji
AU  - Horibe K
AD  - Graduate School of Oral Medicine, Matsumoto Dental University, Nagano, Japan.
FAU - Nakamichi, Yuko
AU  - Nakamichi Y
FAU - Uehara, Shunsuke
AU  - Uehara S
FAU - Nakamura, Midori
AU  - Nakamura M
FAU - Koide, Masanori
AU  - Koide M
FAU - Kobayashi, Yasuhiro
AU  - Kobayashi Y
FAU - Takahashi, Naoyuki
AU  - Takahashi N
FAU - Udagawa, Nobuyuki
AU  - Udagawa N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Immunology
JT  - Immunology
JID - 0374672
RN  - 0 (Antimicrobial Cationic Peptides)
RN  - 0 (Cathelicidins)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (RANK Ligand)
RN  - 0 (Toll-Like Receptors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 12777-81-0 (Flagellin)
RN  - 40013-87-4 (24,25-Dihydroxyvitamin D 3)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - 24,25-Dihydroxyvitamin D 3/immunology
MH  - Animals
MH  - Antimicrobial Cationic Peptides/immunology
MH  - Bone Marrow Cells/immunology/metabolism
MH  - Bone Resorption/etiology/*immunology
MH  - Cathelicidins/pharmacology/*physiology
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Dinoprostone/immunology
MH  - Feedback, Physiological
MH  - Flagellin/immunology
MH  - Lipopolysaccharides/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Osteoblasts/drug effects/*immunology
MH  - Osteoclasts/drug effects/*immunology
MH  - Osteogenesis/drug effects/*immunology
MH  - RANK Ligand/genetics/metabolism
MH  - Toll-Like Receptors/agonists
MH  - Tumor Necrosis Factor-alpha/genetics/metabolism
PMC - PMC3800439
OTO - NOTNLM
OT  - cathelicidin-related antimicrobial peptide
OT  - flagellin
OT  - lipopolysaccharide
OT  - osteoclastogenesis
OT  - receptor activator of nuclear factor-kappaB ligand
EDAT- 2013/07/06 06:00
MHDA- 2013/12/16 06:00
PMCR- 2014/11/01
CRDT- 2013/07/06 06:00
PHST- 2013/02/25 00:00 [received]
PHST- 2013/06/20 00:00 [revised]
PHST- 2013/07/01 00:00 [accepted]
PHST- 2013/07/06 06:00 [entrez]
PHST- 2013/07/06 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PHST- 2014/11/01 00:00 [pmc-release]
AID - 10.1111/imm.12146 [doi]
PST - ppublish
SO  - Immunology. 2013 Nov;140(3):344-51. doi: 10.1111/imm.12146.